CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER 74898

BIOEQUIVALENCE REVIEW(S)

ANDA 74-898

Abbott Laboratories
Attention: Donald Mowles
200 Abbott Park Road
Dept. 389 Bldg. AP30
Abbott Park, IL 60064-3537

MAR 26 1997

Reference is made to your abbreviated new drug application submitted pursuant to Section 505 (j) of the Federal Food, Drug and Cosmetic Act for Iopamidol Injection USP, 41%, 51%, 61%, and 76%.

The Division of Bioequivalence has completed its review and has no further questions at this time.

Please note that the bioequivalency comments expressed in this letter are preliminary. The above bioequivalency comments may be revised after review of the entire application, upon consideration of the chemistry, manufacturing and controls, microbiology, labeling or other scientific or regulatory issues. A revised determination may require additional information and/or studies, or may conclude that the proposed formulation is not approvable.

Sincerely yours,

/S/

for Nicholas Fleischer, Ph.D.
Director, Division of Bioequivalence
Office of Generic Drugs
Center for Drug Evaluation and Research

MAR 24 1997

Iopamidol Injection
41%, 51%, 61%, 76%
in pharmacy bulk package
NDA #74-898
Reviewer: J. Lee
74898W.496

Abbott Laboratories
Abbott Park, Illinois
Submission date:
April 29, 1996
Date accepted for filing:
November 1, 1996

Review of a Request for Waiver

The company has submitted an application for iopamidol injection, 41%, 51%, 61% and 76% in pharmacy bulk packages in flexible plastic (CR3) containers and is seeking a waiver of bioavailability test requirements per 21 CFR 320.22 (b)(1). The Office issued a refuse-to-file letter for the original application, citing several irregularities. The company amended their application per refuse-to-file letter and the application was deemed acceptable for filing on November 1, 1996.

The sponsor claims that their test products are intended for intravascular administration and are identical in active ingredient to the brand product Isovue® (Bracco Diagnostics Inc.).

Formulation comparisons between the test vs reference listed drugs are appended; the formulations are identical in active and inactive ingredients.

The cited reference products are packaged in a glass containers.

Comment:

1. The reviewing chemist should ascertain the suitability of the sponsor's container/closure system.

Recommendation:

1. The Division of Bioequivalence agrees that the information submitted by Abbott Laboratories demonstrates that iopamidol injection, 41%, 51%, 61% and 76% in pharmacy bulk packages fall under 21 CFR 320.22 (b)(1) of Bioavailability/Bioequivalence Regulations. The Division of Bioequivalence recommends that the waiver of an in-vivo bioavailability study be granted. Abbott's test products are deemed bioequivalent to the corresponding strengths of Isovue® pharmacy bulk packages manufactured by Bracco Diagnostics Inc.

/S/

J. Lee
Division of Bioequivalence

5. Formulation Data (Comparison of all Strengths)

A comparison of and the proposed formula follows:

Ingredients per mL	Bracco Diagnostics Inc. Isovue-200 Multipack-PBP (Iopamidol Injection, 41%) in glass containers	Proposed Iopamidol Injection, USP 41%, PBP in Flexible Plastic Containers
Iopamidol	408mg (200 mg I / mL)	408 mg (200 mg I / mL)
Tromethamine	1 mg	1 mg
Edetate Calcium Disodium	0.26 mg	0.26 mg
Hydrochloric Acid*	qs	qs
Sodium Hydroxide*	qs	none present
Water for Injection	qs	qs

* Used for pH adjustment

5. **Formulation Data (Comparison of all Strengths) (continued)**

A comparison of and the proposed formula follows:

Ingredients per mL	Bracco Diagnostics Inc. Isovue-250 Multipack-PBP (Iopamidol Injection, 51%) in glass containers	Proposed Iopamidol Injection, USP 51%, PBP in Flexible Plastic Containers
Iopamidol	510 mg (250 mg I / mL)	510 mg (250 mg I / mL)
Tromethamine	1 mg	1 mg
Edetate Calcium Disodium	0.33 mg	0.33 mg
Hydrochloric Acid*	qs	qs
Sodium Hydroxide*	qs	none present
Water for Injection	qs	qs

* Used for pH adjustment

5. Formulation Data (Comparison of all Strengths) (continued)

A comparison of and the proposed formula follows:

Ingredients per mL	Bracco Diagnostics Inc. Isovue-300 Multipack-PBP (Iopamidol Injection, 61%) in glass containers	Proposed Iopamidol Injection, USP 61%, PBP in Flexible Plastic Containers
Iopamidol	612 mg (300 mg I / mL)	612 mg (300 mg I / mL)
Tromethamine	1 mg	1 mg
Edetate Calcium Disodium	0.39 mg	0.39 mg
Hydrochloric Acid*	qs	qs
Sodium Hydroxide*	qs	none present
Water for Injection	qs	qs

* Used for pH adjustment

5. Formulation Data (Comparison of all Strengths) (continued)

A comparison of and the proposed formula follows:

Ingredients per mL	Bracco Diagnostics Inc. Isovue-370 Multipack-PBP (Iopamidol Injection, 76%) in glass containers	Proposed Iopamidol Injection, USP 76%, PBP in Flexible Plastic Containers
Iopamidol	755 mg (370 mg I / mL)	755 mg (370 mg I / mL)
Tromethamine	1 mg	1 mg
Edetate Calcium Disodium	0.48 mg	0.48 mg
Hydrochloric Acid*	qs	qs
Sodium Hydroxide*	qs	none present
Water for Injection	qs	qs

* Used for pH adjustment